title: Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain.
abstract: BACKGROUND
  NSAIDs are widely used for patients presenting with low back pain. A quick-release formulation of lornoxicam, a potent NSAID from the chemical class of oxicams, offers a faster onset of pain relief compared with the standard tablet formulation.
  
  
  METHODS
  Time to onset of pain relief with lornoxicam was compared with the quick-release formulation of diclofenac potassium in acute low back pain in a randomised, double-blind, multicentre study. 220 patients received either lornoxicam 24 mg or diclofenac potassium 150 mg on day 1 followed by lornoxicam 8 mg twice daily or diclofenac potassium 50 mg twice daily for 5 days. Efficacy outcomes included time to onset of pain relief, as measured by the stopwatch method (primary outcome), pain intensity, pain relief, rescue medication, ability to perform daily activities and global evaluation of the study medication.
  
  
  RESULTS
  The time to onset of pain relief ratios between diclofenac potassium/lornoxicam was 1.03 (95% CI 0.91, 1.26) and 1.05 (95% CI 0.93, 1.29) in the intention-to-treat (ITT) and per-protocol (PP) analyses, respectively, demonstrating the non-inferiority of lornoxicam (defined by lower limits of the 95% CIs >0.80). Time to onset of pain relief was shorter with lornoxicam (30 minutes) compared with diclofenac potassium (36 minutes). The difference was not statistically significant (ITT analysis). A higher magnitude of analgesic effect associated with better global evaluation of the study medication for lornoxicam was also demonstrated. The drugs were equally well tolerated.
  
  
  CONCLUSIONS
  Lornoxicam administered as a quick-release formulation was shown to be non-inferior to the equivalent formulation of diclofenac potassium in terms of onset of pain relief and more effective on most of the major standard efficacy outcomes.
authors.affiliation: Municipal Clinical Hospital #61, Moscow, Russia.
authors.forename: N
authors.initials: N
authors.lastname: Yakhno
authors.forename: A
authors.initials: A
authors.lastname: Guekht
authors.forename: A
authors.initials: A
authors.lastname: Skoromets
authors.forename: N
authors.initials: N
authors.lastname: Spirin
authors.forename: E
authors.initials: E
authors.lastname: Strachunskaya
authors.forename: A
authors.initials: A
authors.lastname: Ternavsky
authors.forename: K J
authors.initials: KJ
authors.lastname: Olsen
authors.forename: P L
authors.initials: PL
authors.lastname: Moller
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced; D000208:Acute Disease; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D004008:Diclofenac / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement / Q000379:methods; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012720:Severity of Illness Index; D013607:Tablets; D013997:Time Factors; D016896:Treatment Outcome; D014581:Urticaria / Q000139:chemically induced
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013607:Tablets; D010894:Piroxicam; D004008:Diclofenac; C059451:lornoxicam